Jinbin Xu

List of Publications by Year
in descending order

75 papers	3,348 citations	109321 35 h-index	149698 56 g-index
81 all docs	81 docs citations	81 times ranked	3779 citing authors

#	Article	IF	Citations
1	Epigenetic Priming of Memory Updating during Reconsolidation to Attenuate Remote Fear Memories. Cell, 2014, 156, 261-276.	28.9	318
2	Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nature Communications, 2011, 2, 380.	12.8	277
3	Alzheimer's Therapeutics Targeting Amyloid Beta 1â€“42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity. PLoS ONE, 2014, 9, e111899.	2.5	151
4	Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Molecular Cancer, 2007, 6, 48.	19.2	118
5	Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5041-5046.	2.2	116
6	Subcellular Localization of Sigma-2 Receptors in Breast Cancer Cells Using Two-Photon and Confocal Microscopy. Cancer Research, 2007, 67, 6708-6716.	0.9	112
7	Fluorine-18-Labeled Benzamide Analogues for Imaging the Ïƒ2 Receptor Status of Solid Tumors with Positron Emission Tomography. Journal of Medicinal Chemistry, 2007, 50, 3194-3204.	6.4	102
8	Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorganic and Medicinal Chemistry, 2005, 13, 77-87.	3.0	99
9	Binding of the Radioligand SIL23 to Î±-Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging Agent. PLoS ONE, 2013, 8, e55031.	2.5	97
10	Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for Î±-Synuclein Fibrils. Journal of Medicinal Chemistry, 2015, 58, 6002-6017.	6.4	92
11	Development of a PET radiotracer for non-invasive imaging of the reactive oxygen species, superoxide, in vivo. Organic and Biomolecular Chemistry, 2014, 12, 4421-4431.	2.8	74
12	The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Molecular Cancer, 2010, 9, 298.	19.2	70
13	Using SV119â€Gold Nanocage Conjugates to Eradicate Cancer Stem Cells Through a Combination of Photothermal and Chemo Therapies. Advanced Healthcare Materials, 2014, 3, 1283-1291.	7.6	69
14	Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. Bioorganic and Medicinal Chemistry, 2014, 22, 1700-1707.	3.0	64
15	Dopamine D1, D2, D3 Receptors, Vesicular Monoamine Transporter Type-2 (VMAT2) and Dopamine Transporter (DAT) Densities in Aged Human Brain. PLoS ONE, 2012, 7, e49483.	2.5	62
16	[3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: A novel sigma-2 receptor probe. European Journal of Pharmacology, 2005, 525, 8-17.	3.5	60
17	Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?. Ageing Research Reviews, 2020, 57, 100994.	10.9	57
18	Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain. Bioorganic and Medicinal Chemistry, 2011, 19, 1666-1673.	3.0	55

#	Article	IF	Citations
19	Cross-Inhibition of NMBR and GRPR Signaling Maintains Normal Histaminergic Itch Transmission. Journal of Neuroscience, 2014, 34, 12402-12414.	3.6	55
20	A Modified Micropipette Aspiration Technique and Its Application to Tether Formation From Human Neutrophils. Journal of Biomechanical Engineering, 2002, 124, 388-396.	1.3	53
21	Synthesis and in Vitro and in Vivo Evaluation of ¹⁸F-Labeled Positron Emission Tomography (PET) Ligands for Imaging the Vesicular Acetylcholine Transporter. Journal of Medicinal Chemistry, 2009, 52, 1358-1369.	6.4	48
22	Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. Nuclear Medicine and Biology, 2010, 37, 509-516.	0.6	48
23	Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3Î±-yl carbamate analogs as Ïƒ2 receptor ligands. Bioorganic and Medicinal Chemistry, 2006, 14, 6988-6997.	3.0	45
24	SV119-gold nanocage conjugates: a new platform for targeting cancer cellsvia sigma-2 receptors. Nanoscale, 2012, 4, 421-424.	5.6	45
25	Synthesis and characterization of selective dopamine D2 receptor ligands using aripiprazole as the lead compound. Bioorganic and Medicinal Chemistry, 2011, 19, 3502-3511.	3.0	43
26	Synthesis and Pharmacological Evaluation of Fluorine-Containing D₃ Dopamine Receptor Ligands. Journal of Medicinal Chemistry, 2011, 54, 1555-1564.	6.4	42
27	Use of Multifunctional Sigma-2 Receptor Ligand Conjugates to Trigger Cancer-Selective Cell Death Signaling. Cancer Research, 2012, 72, 201-209.	0.9	41
28	Quantitative Receptor-Based Imaging of Tumor Proliferation with the Sigma-2 Ligand [18F]ISO-1. PLoS ONE, 2013, 8, e74188.	2.5	41
29	New N-substituted 9-azabicyclo[3.3.1]nonan-3Î±-yl phenylcarbamate analogs as Ïƒ2 receptor ligands: Synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents. Bioorganic and Medicinal Chemistry, 2009, 17, 1222-1231.	3.0	40
30	Endogenous dopamine (DA) competes with the binding of a radiolabeled D₃ receptor partial agonist in vivo: A positron emission tomography study. Synapse, 2011, 65, 724-732.	1.2	39
31	IN VIVO IMAGING IN A MURINE MODEL OF GLIOBLASTOMA. Neurosurgery, 2007, 60, 360-371.	1.1	37
32	Characterization and Evaluation of Two Novel Fluorescent Sigma-2 Receptor Ligands as Proliferation Probes. Molecular Imaging, 2011, 10, 7290.2011.00009.	1.4	37
33	Synthesis and in vivo evaluation of 2 high-affinity 76Br-labeled sigma2-receptor ligands. Journal of Nuclear Medicine, 2006, 47, 1041-8.	5.0	37
34	Synthesis and characterization of selective dopamine D2 receptor antagonists. Bioorganic and Medicinal Chemistry, 2006, 14, 815-825.	3.0	36
35	Sleep deprivation differentially affects dopamine receptor subtypes in mouse striatum. NeuroReport, 2011, 22, 489-493.	1.2	36
36	PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. Experimental Neurology, 2011, 232, 333-338.	4.1	35

#	Article	IF	Citations
37	Functional assays to define agonists and antagonists of the sigma-2 receptor. Analytical Biochemistry, 2014, 448, 68-74.	2.4	35
38	[³H]4â€(dimethylamino)â€Nâ€(4â€(4â€(2â€methoxyphenyl)piperazinâ€1â€yl) butyl)benzamide: A selective radioligand for dopamine D₃ receptors. II. Quantitative analysis of dopamine D₃ and D₂ receptor density ratio in the caudateâ€putamen. Synapse, 2010, 64, 449-459.	1.2	34
39	Synthesis and Structureâ€“Activity Relationship Studies of Conformationally Flexible Tetrahydroisoquinolinyl Triazole Carboxamide and Triazole Substituted Benzamide Analogues as Ïƒ₂ Receptor Ligands. Journal of Medicinal Chemistry, 2014, 57, 4239-4251.	6.4	33
40	Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer. Nuclear Medicine and Biology, 2018, 66, 26-31.	0.6	29
41	Radiosynthesis and biological evaluation of a promising Ïƒ2-receptor ligand radiolabeled with fluorine-18 or iodine-125 as a PET/SPECT probe for imaging breast cancer. Applied Radiation and Isotopes, 2010, 68, 2268-2273.	1.5	28
42	No Differential Regulation of Dopamine Transporter (DAT) and Vesicular Monoamine Transporter 2 (VMAT2) Binding in a Primate Model of Parkinson Disease. PLoS ONE, 2012, 7, e31439.	2.5	28
43	[³H]4â€(Dimethylamino)â€Nâ€[4â€(4â€(2â€methoxyphenyl)piperazinâ€1â€yl)butyl]benzamide, a selective radioligand for dopamine D₃ receptors. I. In vitro characterization. Synapse, 2009, 63, 717-728.	1.2	27
44	Regulation of dopamine presynaptic markers and receptors in the striatum of DJ-1 and Pink1 knockout rats. Neuroscience Letters, 2013, 557, 123-128.	2.1	25
45	Regulation of dopamine D3 receptor in the striatal regions and substantia nigra in diffuse Lewy body disease. Neuroscience, 2013, 248, 112-126.	2.3	25
46	Neuroinflammation and Myelin Status in Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, and Normal Aging Brains: A Small Sample Study. Parkinson's Disease, 2019, 2019, 1-12.	1.1	23
47	Translocator protein in late stage Alzheimerâ€™s disease and Dementia with Lewy bodies brains. Annals of Clinical and Translational Neurology, 2019, 6, 1423-1434.	3.7	22
48	Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes. Molecular Imaging, 2011, 10, 420-33.	1.4	22
49	Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. Bioorganic and Medicinal Chemistry, 2010, 18, 5291-5300.	3.0	20
50	Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents. Biomedicines, 2021, 9, 565.	3.2	18
51	Neuropathic Pain: Biomolecular Intervention and Imaging via Targeting Microglia Activation. Biomolecules, 2021, 11, 1343.	4.0	18
52	The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases. Journal of Neurochemistry, 2020, 152, 235-251.	3.9	17
53	Synthesis and evaluation of in vitro bioactivity for vesicular acetylcholine transporter inhibitors containing two carbonyl groups. Bioorganic and Medicinal Chemistry, 2012, 20, 4422-4429.	3.0	16
54	Sigma-2 receptor binding is decreased in female, but not male, APP/PS1 mice. Biochemical and Biophysical Research Communications, 2015, 460, 439-445.	2.1	16

#	Article	IF	Citations
55	Synthesis and in Vitro Biological Evaluation of Carbonyl Group-Containing Analogues for Ïƒ₁ Receptors. Journal of Medicinal Chemistry, 2011, 54, 5362-5372.	6.4	15
56	Synthesis, pharmacological evaluation and molecular modeling studies of triazole containing dopamine D3 receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 519-523.	2.2	15
57	Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain. Nuclear Medicine and Biology, 2011, 38, 725-739.	0.6	14
58	⁶⁴ Cu-ATSM Positron Emission Tomography/Magnetic Resonance Imaging of Hypoxia in Human Atherosclerosis. Circulation: Cardiovascular Imaging, 2020, 13, e009791.	2.6	13
59	Dopamine D1Â+ÂD3 receptor density may correlate with parkinson disease clinical features. Annals of Clinical and Translational Neurology, 2021, 8, 224-237.	3.7	12
60	PET imaging of in vivo caspase-3/7 activity following myocardial ischemia-reperfusion injury with the radiolabeled isatin sulfonamide analogue [(18)F]WC-4-116. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 110-9.	1.0	11
61	Positron emission tomography imaging of dopamine D2 receptors using a highly selective radiolabeled D2 receptor partial agonist. NeuroImage, 2013, 71, 168-174.	4.2	10
62	Synthesis and inÂvitro evaluation of new analogues as inhibitors for phosphodiesterase 10A. European Journal of Medicinal Chemistry, 2011, 46, 3986-3995.	5.5	8
63	Microglia Implicated in Tauopathy in the Striatum of Neurodegenerative Disease Patients from Genotype to Phenotype. International Journal of Molecular Sciences, 2020, 21, 6047.	4.1	8
64	Striatal oxidative damages and neuroinflammation correlate with progression and survival of Lewy body and Alzheimer diseases. Neural Regeneration Research, 2022, 17, 867.	3.0	8
65	Amino Acid Uptake Measured by [18F]AFETP Increases in Response to Arginine Starvation in ASS1-Deficient Sarcomas. Theranostics, 2018, 8, 2107-2116.	10.0	7
66	Absorbed radiation dosimetry of the D-specific PET radioligand [F]FluorTriopride estimated using rodent and nonhuman primate. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 301-309.	1.0	6
67	Nd-Fe-B permanent magnet generator and voltage stabilizing control technology for vehicles. Advances in Mechanical Engineering, 2016, 8, 168781401666963.	1.6	4
68	The role of beta-arrestin2 in shaping fMRI BOLD responses to dopaminergic stimulation. Psychopharmacology, 2017, 234, 2019-2030.	3.1	4
69	Radiolabeled 6-(2, 3-Dichlorophenyl)-N4-methylpyrimidine-2, 4-diamine (TH287): A Potential Radiotracer for Measuring and Imaging MTH1. International Journal of Molecular Sciences, 2020, 21, 8860.	4.1	3
70	Abstract 356: Photoacoustic imaging of pancreatic cancer proliferation via sigma-2 receptor/PGRMC1-eYFP. Cancer Research, 2012, 72, 356-356.	0.9	1
71	ICâ€Pâ€166: TAU PET IMAGING IN LGI1 ENCEPHALITIS: DECIPHERING THE CONTRIBUTORS TO COGNITIVE IMPAIRMENT IN AUTOIMMUNE ENCEPHALITIS. Alzheimer's and Dementia, 2019, 15, P131.	0.8	0
72	The Striatal DNA Damage and Neurodegenerations. , 0, , .		0

#	Article	IF	Citations
73	Abstract 1054: Identification of progesterone receptor membrane component-1 as the putative sigma-2 receptor. , 2010, , .		0
74	Abstract 5690: Validating sigma-2 receptor ligand as a novel tumor-targeted drug delivery agent for treating ovarian cancer. , 2012, , .		0
75	Dopamine D3 Receptor in Parkinson Disease: A Prognosis Biomarker and an Intervention Target. Current Topics in Behavioral Neurosciences, 2022, , .	1.7	0